Gaudium IVF IPO 2026: Complete Guide with Price, GMP & DRHP Insights
16 February 2026 ·
A comprehensive IPO review covering business model, financials, valuation considerations and listing expectations.
About Gaudium IVF & Women Health Ltd
Incorporated in March 2015, Gaudium IVF and Women Health Limited is engaged in In Vitro Fertilization and assisted reproductive treatments across India.
The company operates using a hub and spoke model with:
Over thirty locations
Seven hubs
Twenty eight spokes
It has centres in major cities including:
Delhi NCR
Mumbai
Bangalore
Patna
Ludhiana
Srinagar
The company also serves international patients from countries including Canada, the United Kingdom, the United States, Kenya, South Africa and Oman.
Gaudium IVF IPO: Key Details
| Parameter | Details |
|---|---|
| IPO Date | 20 to 24 Feb, 2026 |
| Listing Date | Fri, Feb 27, 2026 |
| Face Value | ₹5 per share |
| Price Band | To be announced |
| Lot Size | To be announced |
| Sale Type | Fresh Capital & OFS |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Total Issue Size | 2,08,86,200 shares (agg. up to ₹[.] Cr) |
| Fresh Issue | 1,13,92,500 shares (agg. up to ₹[.] Cr) |
| Offer for Sale | 94,93,700 shares of ₹5 (agg. up to ₹[.] Cr) |
| Share Holding Pre Issue | 6,13,94,384 shares |
| Share Holding Post Issue | 7,27,86,884 shares |
IPO Timetable (Tentative)
| Event | Date |
|---|---|
| IPO Open | Fri, Feb 20, 2026 |
| IPO Close | Tue, Feb 24, 2026 |
| Allotment | Wed, Feb 25, 2026 |
| Refund | Wed, Feb 25, 2026 |
| Credit of Shares | Thu, Feb 26, 2026 |
| Listing | Fri, Feb 27, 2026 |
Business Model and Expansion Strategy
Gaudium IVF operates on an asset light hub and spoke model.
Hub Centres
Fully equipped centres in prime urban locations with advanced IVF laboratories.
Spoke Centres
Partner clinics and alliances to extend reach, increase patient acquisition and improve geographical penetration.
This structure allows:
Lower capital expenditure compared to fully owned centres
Faster expansion across states
Better patient funneling into hub centres
The company has entered into strategic alliances with infertility experts to increase awareness of Assisted Reproductive Technology and IVF treatments.
Services Offered
Gaudium IVF offers specialised fertility treatments including:
In Vitro Fertilization (IVF)
Intracytoplasmic Sperm Injection (ICSI)
Intrauterine Insemination (IUI)
Ovulation induction
It also provides:
Male infertility treatments
Advanced sperm retrieval techniques
PCOD and PCOS treatment
Endometriosis care
High risk pregnancy management
Advanced next generation INTEGRA Ti labs for ICSI and highly technical USG guided services enhance clinical capability.
Competitive Strengths
The company highlights the following strengths:
Patient centric approach
Expert clinical team
Advanced laboratory technology
Established urban hub locations
Asset light business model
The fertility services industry benefits from:
Increasing infertility awareness
Higher disposable incomes
Growing medical tourism
Company Financials (Restated Consolidated)
| Period Ended | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 106.62 | 88.51 | 51.01 | 36.63 |
| Total Income | 49.75 | 70.96 | 48.15 | 44.26 |
| Profit After Tax | 12.51 | 19.13 | 10.32 | 13.53 |
| EBITDA | 18.95 | 28.63 | 19.27 | 20.07 |
| NET Worth | 58.85 | 46.30 | 26.99 | 22.73 |
| Reserves and Surplus | 28.16 | 15.60 | 26.00 | 21.74 |
| Total Borrowing | 22.51 | 18.93 | 15.73 | 9.78 |
Gaudium IVF IPO GMP
The gaudium ivf ipo gmp reflects unofficial grey market trading levels before listing.
Important considerations:
GMP is not regulated
It can fluctuate rapidly
It does not guarantee listing gains
Investors should treat GMP as a sentiment indicator rather than a decision making tool.
Gaudium IVF DRHP: What Investors Should Check
The gaudium ivf drhp is the most important document before applying.
Key sections to review:
Risk factors
Use of IPO proceeds
Expansion plans
Litigation disclosures
Revenue mix
Dependency on key doctors
Healthcare businesses are often dependent on specialist doctors and reputation.
Key Risks
Regulatory changes in healthcare and ART guidelines
Dependency on skilled doctors and embryologists
Reputation risk
Geographic concentration
Competition from established IVF chains
Investors should carefully read the Gaudium IVF DRHP before making decisions.
Final Thoughts from ultra
The gaudium ivf ipo provides exposure to India’s growing fertility services market through a mix of fresh issue and offer for sale.
Before investing, carefully evaluate:
Final gaudium ivf share price band
Financial performance trends
Business scalability
Insights from the gaudium ivf drhp
Market sentiment reflected in gaudium ivf ipo gmp
At ultra, we believe IPO investing should be guided by structured analysis and disciplined evaluation rather than short term excitement.
Disclaimer
This article is for educational purposes only and does not constitute investment advice. Investors should consult a SEBI registered financial advisor and read the Red Herring Prospectus carefully before investing.